Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase i study for the treatment of parkinson disease

Neurosurgery

Volumn 67, Issue 5, 2010, Pages 1377-1385

  Valles, Francisco ^a   Fiandaca, Massimo S ^a   Eberling, Jamie L ^b,c   Starr, Philip A ^a   Larson, Paul S ^a   Christine, Chadwick W ^a   Forsayeth, John ^a   Richardson, R Mark ^a   Su, Xiaomin ^a   Aminoff, Michael J ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

Author keywords

AAV2 hAADC; Convection enhanced delivery; Gene therapy; Magnetic resonance imaging; Parkinson disease; Positron emission tomography

Indexed keywords

6 FLUORO LEVO META TYROSINE F 18; AROMATIC LEVO AMINO ACID DECARBOXYLASE; GADOTERIDOL; PARVOVIRUS VECTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; DRUG INDUCED HEADACHE; EXPERIMENTAL MONKEY; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HUMAN; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SEROTYPE; THALAMUS;

AGED; AROMATIC-L-AMINO-ACID DECARBOXYLASES; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOLECULAR IMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 77958471348     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3181f53a5c     Document Type: Article

References (31)

1. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther. 1975;195(3):453-464.
2. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977;1(8007):345-349.
3. Bankiewicz KS, Forsayeth J, Eberling JL, et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther. 2006;14(4):564-570.
4. Forsayeth JR, Eberling JL, Sanftner LM, et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther. 2006;14(4):571-577.
5. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson's disease. Neurology. 2008;70:1980-1983.
6. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal gene therapy for Parkinson's disease. Neurology. 2009;73(20):1662- 1669.
7. Krauze MT, Saito R, Noble C, et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg. 2005;103(5):923-929.
8. Ashburner J, Friston K. Multimodal image coregistration and partitioning: a unified framework. Neuroimage. 1997;6(3):209-217.
9. Fiandaca M, Varenika V, Eberling J, et al. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage. 2009;47:T27-T35.
10. Yin D, Valles FE, Fiandaca MS, et al. Striatal volume differences between non-human and human primates. J Neurosci Methods. 2009;176:200-205.
11. Cunningham J, Pivirotto P, Bringas J, et al. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther. 2008;16(7):1267-1275.
12. Bankiewicz KS, Daadi M, Pivirotto P, et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol. 2006;197(2):363-372.
13. Di Stefano A, Sozio P, Cerasa LS. Antiparkinson prodrugs. Molecules. 2008;13(1):46-68.
14. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys: in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol. 2000;164(1):2-14.
15. Eberling JL, Jagust WJ, Taylor S, et al. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes. Brain Res. 1998;805(1-2):259-262.
16. Doudet DJ, Chan GL, Jivan S, et al. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-l-dopa vs 6-[18F]fluoro-l-m-tyrosine. J Cereb Blood Flow Metab. 1999;19(3):278-287.
17. Daadi MM, Pivirotto P, Bringas J, et al. Distribution of AAV2-hAADC-transduced cells after 3 years in parkinsonian monkeys. Neuroreport. 2006;17(2):201-204.
18. Saito R, Krauze MT, Bringas JR, et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol. 2005;196(2):381-389.
19. Varenika V, Dickenson P, Bringas J, et al. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg. 2008;109:874-880.
20. Levy RM, Major E, Ali MJ, Cohen B, Groothius D. Convection-enhanced in-traparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML). J Neurovirol. 2001;7(4):382-385.
21. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cin-tredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007;25(7):837-844.
22. Krauze MT, Vandenberg SR, Yamashita Y, et al. Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp Neurol. 2008;210(2):638-644.
23. Runge VM, Kuehl TJ, Jackson CB, Estrada EA. Subchronic toxicity of the gadolinium chelates. Acad Radiol. 2005;12(Suppl 1):S6-S9.
24. Thomsen HS. Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol. 2004;14(9):1654-1656.
25. Richardson RM, Varenika V, Forsayeth JR, Bankiewicz KS. Future applications: gene therapy. In: Larson PS, Lim DA, eds. Intraoperative MRI in Functional Neurosurgery. Philadelphia, PA: W.B. Saunders Co; 2009:219-224.
26. Yin D, Valles FE, Fiandaca MS, et al. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates [published online ahead of print September 15, 2009]. Neuroimage. doi: 10.1016/j.neuroimage.2009.08.069.
27. Szerlip NJ, Walbridge S, Yang L, et al. Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg. 2007;107(3):560-567.
28. Hadaczek P, Kohutnicka M, Krauze MT, et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther. 2006;17(3):291-302.
29. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci \USA. 1994;91(6):2076-2080.
30. Sykova E. Diffusion properties of the brain in health and disease. Neurochem Int. 2004;45:453-466.
31. Krauze MT, Forsayeth J, Park JW, Bankiewicz KS. Real-time imaging and quantification of brain delivery of liposomes. Pharm Res. 2006;23(11):2493-2504.